TAUVID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tauvid, and when can generic versions of Tauvid launch?
Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-six patent family members in sixteen countries.
The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Tauvid
Tauvid will be eligible for patent challenges on May 28, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAUVID
International Patents: | 26 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 9 |
Patent Applications: | 9 |
What excipients (inactive ingredients) are in TAUVID? | TAUVID excipients list |
DailyMed Link: | TAUVID at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAUVID
Generic Entry Date for TAUVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAUVID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Phase 1 |
Avid Radiopharmaceuticals | Phase 2 |
Avid Radiopharmaceuticals | Phase 1 |
US Patents and Regulatory Information for TAUVID
TAUVID is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAUVID is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAUVID
Imaging agents for detecting neurological dysfunction
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting TAUVID
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-002 | May 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TAUVID
When does loss-of-exclusivity occur for TAUVID?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 12381042
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 15390
Estimated Expiration: ⤷ Try a Trial
Patent: 73963
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4781234
Estimated Expiration: ⤷ Try a Trial
Patent: 7011342
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 31359
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0220401
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
Patent: 99763
Estimated Expiration: ⤷ Try a Trial
Patent: 52572
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 58352
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 76206
Estimated Expiration: ⤷ Try a Trial
Patent: 11512354
Estimated Expiration: ⤷ Try a Trial
Patent: 15517572
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 47558
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1609504
Estimated Expiration: ⤷ Try a Trial
Patent: 100135235
Estimated Expiration: ⤷ Try a Trial
Patent: 150002854
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 92830
Estimated Expiration: ⤷ Try a Trial
Patent: 07992
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAUVID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 2247558 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2009102498 | ⤷ Try a Trial | |
Spain | 2792830 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |